Abstract
Microglial p300-mediated translocation of HMGB1 in the PVN may be a fundamental epigenetic mechanism in NMDAR-mediated central sympathetic activation post-MI, suggesting targeting p300 signaling modulation in the PVN as a potential antiarrhythmic therapy.
Introduction: The Brain-Heart Connection in Cardiac Distress
Following a myocardial infarction (MI), the body’s sympathetic nervous system—the "fight or flight" response—often enters a state of pathological overdrive. This hyperactivation is a primary driver of fatal ventricular arrhythmias (VAs) and sudden cardiac death. While the hypothalamic paraventricular nucleus (PVN) is recognized as a command center for this response, the precise molecular mechanisms linking neuroinflammation in the brain to electrical instability in the heart have remained poorly understood.
Researchers investigated whether protein acetylation, a post-translational modification acting as an epigenetic switch, serves as the missing link. Specifically, they focused on the acetyltransferase p300 and its role in modifying the brain's immune environment to drive cardiac sympathetic activation.
The Microglia-Neuron Relay
The study identifies a specific signaling axis within the PVN. Post-MI, p300 is significantly upregulated specifically within the microglia. This enzyme acts on High-mobility group protein B1 (HMGB1), a protein typically found in the nucleus.
Acetylation of HMGB1 at the K43 site by p300 serves as a molecular "passport," enabling its translocation from the nucleus to the cytoplasm and subsequent secretion. Once released into the extracellular space, HMGB1 binds to NMDAR subunits (GluN1 and GluN2B) on pre-autonomic neurons. This interaction increases excitatory currents, effectively amplifying the sympathetic signals sent to the heart.
Key Results and Empirical Evidence
Experimental data confirmed that p300 expression in the PVN increases progressively following MI, peaking between days 3 and 5. This increase is localized to Iba1-positive microglia.
Key findings from the study include:
- Sympathetic Reduction: Silencing p300 in the PVN using AAV-shRNA significantly reduced peripheral renal sympathetic nerve activity (RSNA) and lowered cardiac norepinephrine levels.
- Anti-Arrhythmic Efficacy: p300 knockdown decreased susceptibility to ventricular arrhythmias and improved cardiac ejection fraction (from ~40% to ~49% in treated rats).
- Molecular Validation: Mutating the K43 site on HMGB1 (K43R) successfully blocked its nuclear export, confirming it as the critical regulatory switch.
- Neuronal Firing: Patch-clamp recordings demonstrated that exogenous HMGB1 increases NMDAR-mediated currents, an effect that was abolished by the NMDAR blocker MK-801.
Methods and Datasets
The researchers employed a multi-disciplinary approach:
- Animal Models: Rat MI models established via coronary artery ligation.
- Proteomics: Shotgun proteomics and "acetylome" analysis on human HMC3 microglial cells identified 135 differentially acetylated proteins targeted by p300.
- Electrophysiology: Measurement of RSNA and brain slice patch-clamp recordings.
- Computational Modeling: Protein-protein docking analysis to predict HMGB1-NMDAR interactions.
Discussion and Future Directions
While promising, the study notes limitations, including the use of acute rat ligation models which may not fully capture the complexity of human coronary artery disease. Additionally, the challenge of efficiently targeting microglia with viral vectors remains a hurdle for clinical translation. Future research will focus on developing site-specific deacetylation techniques to provide a precision therapeutic strike against sympathetic storms without disrupting broader epigenetic functions.
Summary updated